New drug shows promise for lung scarring disease
NCT ID NCT02503657
First seen Jan 25, 2026 · Last updated May 25, 2026 · Updated 22 times
Summary
This study tested a drug called MN-001 in 15 people with moderate to severe idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. Participants took either MN-001 or a placebo twice daily for 6 months, followed by an open-label phase where everyone could receive the drug. The main goal was to see if MN-001 could improve lung function, measured by forced vital capacity (FVC), and to check its safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Penn State University College of Medicine, Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
Conditions
Explore the condition pages connected to this study.